Zobrazeno 1 - 10
of 16
pro vyhledávání: '"D R, Gehlert"'
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 293(1)
1229U91 (GW1229 or GR231118) [lle,Glu,Pro,Dpr,Tyr, Arg,Leu,Arg, Tyr-NH(2))2 cyclic (2,4'),(2'4)-diamide] has been reported by several research groups to be a potent antagonist at the Y1 neuropeptide Y (NPY) receptor subtype. However, 1229U91 also dis
Autor:
D R, Gehlert, L, Dreshfield, F, Tinsley, M J, Benvenga, S, Gleason, R W, Fuller, D T, Wong, S K, Hemrick-Luecke
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 287(1)
The compound, LY368975 ((R)-thionisoxetine) is a potent and selective inhibitor of the norepinephrine (NE) reuptake site. We evaluated the in vivo properties of LY368975 in various animal models. In mice, LY368975 prevented heart NE depletion by 6-hy
Autor:
S, Iyengar, P A, Hipskind, D R, Gehlert, D, Schober, K L, Lobb, J A, Nixon, D R, Helton, M J, Kallman, S, Boucher, R, Couture, D L, Li, R M, Simmons
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 280(2)
The selective neurokinin (NK)-1 antagonist LY303870 has high affinity and specificity for human and guinea pig brain NK-1 receptors labeled with 125I-substance P. It has approximately 15- to 30-fold lower affinity for rat and mouse brain NK-1 recepto
Autor:
D R, Gehlert, D A, Schober, L, Beavers, R, Gadski, J A, Hoffman, D L, Smiley, R E, Chance, I, Lundell, D, Larhammar
Publikováno v:
Molecular pharmacology. 50(1)
Traditionally, neuropeptide Y (NPY) receptors have been divided into Y1 and Y2 subtypes based on peptide pharmacology and synaptic localization. Other receptor subtypes have been proposed based on preferences for NPY, peptide YY (PYY), or pancreatic
Publikováno v:
Molecular pharmacology. 49(2)
The 36-amino acid peptide, neuropeptide Y (NPY), is a member of a peptide family that includes the endocrine peptides, peptide YY (PYY), and pancreatic polypeptide (PP). NPY receptors have been broadly subdivided into postsynaptic Y1 receptors and pr
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 274(3)
Quinelorane is a BCD partial ergoline with potent dopaminergic effects in vitro and in vivo. Partial ergoline compounds of this series consist of the B-, C- and D-rings of the four ring ergoline skeleton. Many of the pharmacological effects of quinel
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 257(2)
We have developed a high specific activity ligand for localization of ATP-sensitive potassium channels in the brain. When brain sections were incubated with [125I]iodoglyburide (N-[2-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]ethyl]-5-125I-2- methox
Autor:
D. R. Gehlert, F. C. Tinsley, D. Zimmerman, P. A. Hipskind, H. Zarrinmayeh, T. Britton, R. F. Bruns, S. Iyengar
Publikováno v:
Behavioural Pharmacology. 9:S40
Publikováno v:
Journal of chemical neuroanatomy. 2(3)
The distribution of dopamine type 1 (D-1) and dopamine type 2 (D-2) receptors in the brain have been compared as assessed by the technique of autoradiography after labelling with highly selective ligands. D-1 receptors, as evidenced by the specific b
Publikováno v:
Advances in experimental medicine and biology. 175